Skip to main content

TBC Novartis Pharmaceuticals Australia Pty Ltd

Product name
TBC
Accepted date
Oct-2023
Active ingredients
ribociclib succinate
Proposed indication
Is indicated for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer.
Application type
C (new indication)
Publication date
Oct-2023

Help us improve the Therapeutic Goods Administration site